Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemother...
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2200
- Registration Number
- NCT00070122
- Locations
- ๐บ๐ธ
Southwest Oncology Group, San Antonio, Texas, United States
Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 80
- Registration Number
- NCT00070265
- Locations
- ๐บ๐ธ
University of Texas, Houston, Texas, United States
Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 460
- Registration Number
- NCT00070213
- Locations
- ๐ฌ๐ง
Medical Research Council Clinical Trials Unit, London, England, United Kingdom
๐ฌ๐งCookridge Hospital, Leeds, England, United Kingdom
๐ฌ๐งClinical Trials and Research Unit of the University of Leeds, Leeds, England, United Kingdom
S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00070434
A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-09-18
- Last Posted Date
- 2020-03-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1886
- Registration Number
- NCT00069121
- Locations
- ๐บ๐ธ
New Mexico Oncology Hematology Consultants, Albuquerque, New Mexico, United States
๐บ๐ธInnovative clinical research institute/American institute of research, Whittier, California, United States
๐บ๐ธNh Oncology Hematology, Pa, Hooksett, New Hampshire, United States
GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2014-10-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00068588
- Locations
- ๐บ๐ธ
University of California Davis Cancer Center, Sacramento, California, United States
Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 86
- Registration Number
- NCT00064181
- Locations
- ๐ช๐ฌ
National Cancer Institute - Cairo, Cairo, Egypt
๐ญ๐บNational Institute of Oncology, Budapest, Hungary
๐ฉ๐ชWestpfalz-Klinikum GmbH, Kaiserslautern, Germany
Oxaliplatin and Bevacizumab (Avastinโข) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer
- Conditions
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Prologue Research International
- Registration Number
- NCT00062426
- Locations
- ๐บ๐ธ
Physicians East - Quadrangle, Greenville, North Carolina, United States
๐บ๐ธNorthwestern Connecticut Oncology-Hematology Associates, Torrington, Connecticut, United States
๐บ๐ธJackson Oncology Associates, PLLC, Jackson, Mississippi, United States
Oxaliplatin Plus Capecitabine in Treating Patients With Metastatic or Recurrent Solid Tumor
- Conditions
- First Posted Date
- 2003-04-21
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT00005839
- Locations
- ๐บ๐ธ
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
๐บ๐ธBeckman Research Institute, City of Hope, Los Angeles, California, United States
๐บ๐ธUniversity of California Davis Cancer Center, Sacramento, California, United States
S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2012-11-02
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 43
- Registration Number
- NCT00058318
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.